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Abstract
Metastatic melanoma is the most aggressive form of
skin cancer with a median overall survival of less than
one year. Advancements in our understanding of how
melanoma evades the immune system as well as the
recognition that melanoma is a molecularly
heterogeneous disease have led to major
improvements in the treatment of patients with
metastatic melanoma. In 2011, the US Food and Drug
Administration (FDA) approved two novel therapies
for advanced melanoma: a BRAF inhibitor,
vemurafenib, and an immune stimulatory agent,
ipilimumab. The success of these agents has injected
excitement and hope into patients and clinicians and,
while these therapies have their limitations, they will
likely provide excellent building blocks for the next
generation of therapies. In this review we will discuss
the advantages and limitations of the two new
approved agents, current clinical trials designed to
overcome these limitations, and future clinical trials
that we feel hold the most promise.
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Introduction
With approximately 13,000 annual deaths and a median
overall survival (OS) of 8 to 18 months, metastatic mela-
noma is the most aggressive form of skin cancer [1].
Until 2011, only two FDA therapies for metastatic mela-
noma were approved, dacarbazine and high dose inter-
leukin 2 (HD IL-2), both of which do not increase
median OS [2-4]. Dacarbazine is limited by a low
response rate (10% to 15%) and an overall survival of
eight months [2]. HD IL-2 is limited by an even lower
response rate (6% to 10%) and severe toxicity with only
a minority of patients achieving a long-term, durable
response [3,4].
Recognition of key molecular mutations that drive
tumorigenesis in melanoma has led to the development
of promising agents that selectively target and inhibit
these mutations and, in turn, provide improved response
rates with decreased toxicity. Secondarily, advancements
in our understanding of tumor immunology and
immune escape have led to the emergence of newer
immunologic agents that are less toxic than HD IL-2
but still provide long-term benefits. While these break-
throughs are encouraging, several limitations remain. In
the case of vemurafenib, the duration of response is
relatively short. In the case with ipilimumab, the
response rate is low. The purpose of this review is to
summarize the recent advances in the treatment of
metastatic melanoma, further describe the current lim-
itations, and comment on promising future strategies to
overcome these limitations.
Recent advances
BRAF inhibitors
In 2002, it was discovered that cutaneous melanoma is a
molecularly heterogeneous disease with approximately
40% to 60% harboring an activating mutation in the
gene encoding for the serine/threonine kinase protein
kinase B-raf (BRAF) with 90% of the mutations resulting
in a substitution of valine for glutamate at amino acid
600 (V600E) [5-8]. Mutated BRAF leads to constitutive
activation of the mitogen-activated protein kinase path-
way (MAPK) that in turn increases cellular proliferation
and drives oncogenic activity. Given the relatively high
incidence of mutant BRAF as well as its oncogenic
potential, investigators have long sought to selectively
inhibit mutated BRAF. Earlier attempts to inhibit BRAF
in patients with melanoma with sorafenib were largely
unsuccessful secondary to the poor sensitivity of sorafe-
nib to selectively target mutant BRAF that led to intoler-
able off-target side effects through inhibition of wild-
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any medium, provided the original work is properly cited.type BRAF and other off-target effects [9-13]. Recently,
highly selective BRAF inhibitors capable of silencing
mutant BRAF (V600E) with little effect on wild-type
BRAF have emerged (Table 1). In a phase 1 study, the
first of these selective BRAF inhibitors, vemurafenib,
demonstrated substantial tumor regression in 81% of
patients with metastatic melanoma who had a BRAF
(V600E) mutation and received the recommended phase
2 dose [13,14]. The follow up phase 2 (BRIM2) study of
previously treated patients demonstrated a confirmed
response rate (RR) of 53% with a 6.8 month median
duration of response [15]. Finally, a phase 3 randomized
control trial (BRIM3) of previously untreated patients
compared vemurafenib to dacarbazine demonstrating
improvements in RR (48% versus 5%), progression free
survival (5.3 versus 1.6 months), percent of patients
alive at six months (84% versus 64%) with a 75% reduc-
tion in risk of death [16]. A second BRAF inhibitor,
GSK2118436, showed similar efficacy in a phase 1/2
study although OS data are not yet mature [17]. In addi-
tion, 10% to 30% of patients with a BRAF mutation have
a non-V600E mutation with the most common non-
V600E mutation being V600K which is present in 5% to
20% of melanoma patients with a BRAF mutation [7,18].
Both vemurafenib and GSK2118436 have shown activity
in V600K mutant melanomas and while vemurafenib is
not currently approved for patients with V600K muta-
tions, further studies are examining its efficacy in non-
V600E mutant patients [16,19]. Finally, both vemurafe-
nib and GSK2118436 have been tested in patients with
brain metastasis with apparent activity in the brain
although the number of treated patients remains small
at present [19,20]. In summary, both highly selective
BRAF inhibitors, vemurafenib and GSK2118436, have
demonstrated excellent clinical activity with a high
response rate and low toxicity in patients with BRAF
V600E mutations but, unfortunately, both therapies are
l i m i t e db yar e l a t i v e l ys h o r td u r a t i o nt h a ta v e r a g e s
around six months. The most important toxicity related
to BRAF inhibitors is accelerated growth of cutaneous
squamous cell carcinomas (SCC) and keratoacanthomas
through paradoxical activation of MAPK signaling
occurring in approximately 20% of patients [21].
Fortunately, these SCC are easily removed and cured
through local excision.
Ipilimumab
Melanoma is characterized as one of the most immuno-
g e n i ct u m o r sd u et ot h ep r e s e n c eo ft u m o ri n f i l t r a t i n g
lymphocytes in resected melanoma, occasional sponta-
neous regressions, and clinical responses to immune sti-
mulation. The immunogenicity of melanoma has led
investigators to study novel immune strategies to over-
come tumor immune evasion. One mechanism by which
T cells self-regulate their activation is through expres-
sion of cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4). CTLA-4 functions as a negative co-stimula-
tory molecule for the T cell, and therapies that antago-
nize CTLA-4 remove the brakes from the T cell leading
to a net effect of T cell hyper-responsiveness [22]. Ipili-
mumab is a fully human IgG1 monoclonal antibody that
blocks CTLA-4, thereby increasing T-cell activity and
promoting antitumor activity [23]. Two phase 3 rando-
mized clinical trials have evaluated ipilimumab in meta-
static melanoma [23,24]. In the first trial of patients
with previously treated unresectable stage III or IV mel-
anoma, ipilimumab demonstrated an improved overall
survival versus glycoprotein 100 peptide vaccine (gp100)
(10.1 versus 6.4 months) [24]. In the second phase 3
trial in previously untreated patients with metastatic
melanoma, ipilimumab plus dacarbazine demonstrated
improvement in OS versus single agent dacarbazine
(11.2 versus 9.2 months) [23]. In both phase 3 studies,
the response rate, complete response (CR) and partial
response (PR) was only 10% to 15% and the disease con-
trol rate (CR, PR, and stable disease (SD)) was approxi-
mately 30%. In addition, the improvement in percent of
patients alive at one and two years is consistently 10%
better than the non-ipilimumab containing arms (Table
2). While the response rate and improvement in OS in
ipilimumab is relatively modest, the toxicities of the
therapy, including immune-related enterocolitis, hepati-
tis, and dermatitis, are highly manageable [24].
Future strategies
The recent success of both vemurafenib and ipilimumab
instilled hope into physicians and patients with meta-
static melanoma; however, the limitations of both
Table 1 Summary of BRAF inhibitor trials
Trial Patients RR
%
PFS
(months)
OS
(years)
Number
(Patients)
Summary
Phase 2
Ribas et al.
[15]
Vemurafenib in previously
treated metastatic melanoma
52 6.2 Not yet
reached
132 Met primary end point of best overall survival target of 30%
(95% CI: 43 to 61%)
Phase 3
Chapman
et al. [16]
Vemurafenib
versus
dacarbazine in untreated
metastatic melanoma
48
v
5
5.3
v
1.6
Not yet
reached
675 Compared vemurafenib and dacarbazine with co-primary
endpoints of overall survival and progression free survival.
84% vs 64% OS at 6 months (95% CI: 78 to 89)
OS, overall survival; PFS, progression free survival; RR, response rate.
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treatment strategies. One of the major challenges in
overcoming the limitations of these novel therapies is
both increasing the duration of response to BRAF inhi-
bitors and improving the response rate of ipilimumab.
We will discuss multiple strategies to address the limita-
tions of vemurafenib below.
Overcoming resistance to BRAF inhibitors using
additional targeted therapies
While selective BRAF inhibitors have provided a major
breakthrough in the treatment of melanoma, resistance
to therapy invariably develops with the median duration
of benefit of approximately six months (Figure 1).
Mutant BRAF drives melanoma tumor proliferation
through activation of the mitogen activated kinase path-
way (MAP) pathway, and resist a n c et oB R A Fi n h i b i t o r s
has been described in both MAP kinase-dependent and
-independent pathways [25-27]. MAP kinase-dependent
pathways of resistance include secondary NRAS muta-
tions, elevated expression of COT kinase, CRAF activa-
tion, and acquired MEK1 mutation [25,28-31]. MAP
kinase-independent pathways include upregulation of
PDGFR, additional receptor tyrosine kinases activation
including AXL, ERBB4, and IGF1R, activation of PI3K/
AKT signaling, and loss of PTEN [25,29,31-35]. Strate-
gies to overcoming these mechanisms of resistance are
currently being developed. A recent phase 1/2 study
combining an oral MEK 1/2 inhibitor GSK1120212 with
BRAF inhibitor GSK2118436 was well tolerated [36], but
it is too early to determine if the combination will
increase the duration of response of a single agent
BRAF inhibitor. A randomized phase 3 study set to
begin in 2012 will hopefully address this question. Addi-
tional future targeted combinations will likely include
BRAF inhibitors with PI3K, PDGFR, IGF1R, MEK, or
ERBB4 inhibitors and will be expanded upon below.
Improving upon ipilimumab
While ipilimumab is capable of inducing long-term
responses in a minority of patients, the relatively low
response rate (10% to 15%) and meager improvement in
median survival (two months) limit its utility. A key
area of improving the clinical benefit of ipilimumab is to
increase the response rate either through improved
patient selection or through combination with other
therapies. At present, therei sn or e l i a b l ep r e d i c t o ro f
benefit for ipilimumab. One group recently reported
that the presence of a BRAF mutation does not predict
clinical benefit of ipilimumab [37]. Other groups have
shown that ipilimumab increases the frequency of T
cells with inducible co-stimulatory molecule (ICOS) [38]
and that ICOS T cells are necessary for response to ipi-
limumab [39]. Whether or not baseline ICOS T cells
predict benefit to ipilimumab remains to be determined.
Finally, there is ample evidence to suggest that a higher
dose of ipilimumab (10 mg/kg) results in an increased
response than the approved dose (3 mg/kg) and a ran-
domized phase 3 study is underway to address this
question.
In addition to improved patient identification, many
investigators are combining ipilimumab with other treat-
ment modalities in order to increase the response rate.
As mentioned above, the phase 3 study of dacarbazine
plus ipilimumab did not yield a higher than expected
response rate; however, this study was not designed to
answer this question. In a randomized phase 2 study of
ipilimumab versus ipilimumab and dacarbazine, the ipili-
mumab/dacarbazine combination resulted in an
increased response rate (15% versus 5%) and improved
one-, two-, and three-year survival [40]. In a single arm
phase 2 study, the combination of ipilimumab and
temozolamide resulted in an overall disease control rate
(CR/PR and SD) of 67% which is much higher than seen
in single agent studies [41]. A phase 1 study testing the
Table 2 Summary of Ipilimumab Trials
Trial Patients RR%
(CR/
PR)
PFS
(months)
OS
(years)
Number
(patients)
Summary
Phase 3
Hodi et
al. [24]
Ipilimumab plus gp100
versus
Ipilimumab alone
versus
gp100 alone
previously treated metastatic melanoma
5.7
versus
10.9
versus
1.5
2.76
versus
2.86
versus
2.76
10.0
versus
10.1
versus
6.4
676 Ipilimumab with significant improvement in OS
versus gp-100.
Phase 3
Robert
et al.
[23]
Ipilimumab plus dacarbazine
versus
dacarbazine in untreated metastatic melanoma
15.2
versus
10.3
Not
stated
11.2
versus
9.1
502 Ipilimumab plus dacarbazine significantly with
significant improvement in OS over dacarbazine.
Phase 2
Hersh et
al. [40]
Ipilimumab
versus
Ipilimumab plus dacarbazine in chemotherapy
naïve patients with metastatic melanoma
5.3
versus
14.3
Not
stated
11.4
versus
14.4
72 Ipilimumab plus dacarbazine improved RR and
OS compared to single agent ipilimumab.
CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.
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a RR of 36% and overall disease control rate of 67%, but
immune-related adverse reactions also seemed to be
greatly enhanced with this combination [42]. Ipilimumab
is also being combined with multiple other agents
including granulocyte-macrophage colony-stimulating
factor (GM-CSF), vaccines and other immune modula-
tors with a goal to overcoming the immune tolerance of
melanoma. In summary, there is no agent that is proven
to increase the response rate of ipilimumab in a phase 3
trial and until that evidence exists, we do not recom-
mend combining ipilimumab with any other therapy
outside the setting of a clinical trial.
Ipilimumab combined with radiation
Finally, an additional area of research to improve on
the success of ipilimumab is through the combination
of ipilimumab with radiation therapy with two trials
currently enrolling patients. The first is a pilot study of
ipilimumab in stage IV melanoma patients who are
receiving palliative radiation therapy [43]. The second
is the RADVAX study, a stratified phase 1/2 dose esca-
lation trial of stereotactic body radiotherapy followed
by ipilimumab in patients with metastatic melanoma
[43]. The toxicity profile of this combination therapy
will be of interest as both therapies can elicit similar
toxicities such as colitis [44]. Trials combining vemur-
afenib and radiation therapy are also in the planning
phases.
Additional targeted therapies
As mentioned above, approximately 50% of patients
with melanoma harbor BRAF mutations and are eligible
for treatment with the novel BRAF inhibitors. In addi-
tion to BRAF, other mutations in genes as well as altera-
tions in cancer related pathways have been identified in
Baseline 2 weeks 6 months
Figure 1 Typical response for patients on BRAF inhibitors. BRAF inhibitors can induce positron emission tomography (PET) responses in as
little as two weeks but unfortunately most patients developed relapse and progressive disease at about six months. This patient was treated in
the phase 1 study of PLX4032 (vermurafenib).
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target these pathways as well.
C-KIT (ED Query: I wasn’t sure if this should be in all caps
or all lower case so I left it as the authors had it.)
c-kit, also known as CD117, is a receptor tyrosine kinase
that is mutated in approximately 20% of acral, mucosal,
and chronically sun-damageds k i n[ 4 5 ] .T h el i g a n df o r
KIT is stem cell factor (SCF) and binding of SCF to c-
kit induces activation of downstream signaling pathways
that are involved in mediating growth and survival sig-
nals within the cell including the P13K-AKT-mTOR
pathway and the RAS-RAF-MEK-ERK pathway. KIT has
been implicated in the pathogenesis of several cancers
including acute myeloid leukemia and gastrointestinal
stromal tumors (GIST) [46-49]. Unlike in GIST where
c-kit mutations tend to be deletions or insertions in
exon 11, c-kit mutations in melanoma occur at multiple
sites along the gene including both the juxta-membrane
domain at exon 11 and exon 13 and the kinase domain
at exon 17 and are usually point mutations that do not
correlate with KIT copy number or CD117 expression
[50,51].
Imatinib, an oral tyrosine kinase inhibitor with known
activity against c-kit activated tumors, was tested in
three phase 2 studies of patients with melanomas that
harbor c-kit mutations [52-54]. The first study enrolled
patients with metastatic melanoma who expressed at
least one protein tyrosine kinase (c-kit, platelet derived
growth factor receptors, c-abl, or abl related gene)
demonstrating a response in only one patient, interest-
ingly in the patient who had the highest level of c-kit
expression [52]. Of note, mutations in c-kit were not
required prior to entry in this study. In the second
study, 28 patients with c-kit mutations and amplifica-
tions with advanced unresectable melanoma arising
from acral, mucosal, and chronically sun-damaged sites
were treated with imatinib mesylate 400 mg orally twice
daily in six-week cycles until disease progression or
unacceptable toxicity [54]. Durable overall response rate
(ORR) was 16% with a median time to progression of 12
weeks and median OS of 46.3 weeks. The third study
enrolled 43 patients with c-kit mutated metastatic mela-
noma treated with imatinib who demonstrated an ORR
of 23.3% and median OS of 14 months, with 51% alive
at one year [53]. Please see Table 3 for a summary of
these three trials. In summary, the responses to imatinib
were primarily demonstrated in patients harboring
mutations in c-kit at exon 11 or exon 13. Activity of
dasatinib in c-kit mutated melanoma has already been
demonstrated and additional trials with imatinib, niloti-
nib, and dasatinib are currently ongoing [43,50,55]. As is
the case with the BRAF inhibitors, combinations of c-kit
inhibitors with cyotoxic agents, immunotherapies, and
other targeted therapies are underway.
ERBB4
ERBB4 (HER4) is a protein tyrosine kinase that activates
both the ERK and AKT signaling pathways [56,57]. In a
genome wide search of the tyrosine kinome, ERBB4
mutations were identified in 19% of patients with mela-
noma. In vitro assays demonstrated that lapatinib, a
pan-ERBB inhibitor had activity in cell lines with these
mutations and not in cell lines without these mutations
[58]. In this same study, it was noted the ERBB4 muta-
tions were found in patients with and without BRAF
mutations suggesting that ERBB4 is perhaps an indepen-
dent and complementary driver of tumorigenesis. A
phase 2 trial of lapatanib in stage IV melanoma patients
who harbor an ERBB4 mutation is currently enrolling
[43]. Future therapeutic combinations of lapatinib and
other ERBB4 inhibitors with either other targeted,
immune, or chemotherapeutic agents hold promise.
VEGF
Vascular endothelial growth factor (VEGF) as a media-
tor of tumor associated angiogenesis plays an essential
role in the progression of melanoma [59]. The vascular
radial and vertical growth patterns of melanoma are
associated with rapid progression and metastasis, indica-
tive of a therapeutic role for VEGF inhibition [60]. As
single agents, anti-VEGF therapies have not demon-
strated much success in patients with metastatic mela-
noma, but when combined with chemotherapy and
immunotherapy there is some hint that anti-VEGF ther-
apy has a future in the treatment of patients with meta-
static melanoma. In a single arm phase 2 study of
carboplatin, paclitaxel, and bevacizumab in patients with
stage IV melanoma the RR was 17% with a median pro-
gression free survival (PFS) of six months and median
OS of 12 months [61]; however, a randomized phase 2
trial of carboplatin and paclitaxel plus or minus bevaci-
zumab failed to demonstrated significant improvement
in OS (12.3 versus 8.6, P = 0.17) [62]. A single arm
phase 2 study in chemotherapy naïve (CN) patients and
previously treated (PT) patients tested the combination
of bevacizumab with nab-paclitaxel and carboplatin and
demonstrated a RR of 25.6% (CN) and 8.8% (PT) with
median PFS of 4.5 (CN) months and 4.1 (PT) months
and OS of 11.1 (CN) months and 10.1 (PT) months
[63]. This combination is moving forward for a phase 3
evaluation. A multi-center phase 2 study of axitinib, an
oral second-generation inhibitor of VEGF receptor-1, 2,
and 3 demonstrated a RR of 19% with a median PFS of
3.9 months and median OS of 6.6 months [64]. In addi-
t i o n ,as e p a r a t eV E G Fr e c e p t o r - 1 ,2 ,a n d3i n h i b i t o r ,
E7080 or lenvatinib, demonstrated a RR of 21% in phase
1 evaluation of patients with solid tumors including
patients with melanoma [65]. Taken together, inhibiting
the VEGF pathway is likely beneficial for a subset of
Finn et al. BMC Medicine 2012, 10:23
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hopefully lead to clinically meaningful improvements in
patient outcomes. Please see Table 4 summarizing the
above trials involving VEGF in melanoma.
Future of immunotherapy
PD-1/PD-L1
One mechanism by which melanoma is thought to
evade the immune system is through tumor expression
of programmed death ligand 1 (PD-L1). PD-L1 is a
negative regulator of the immune system that acts
through binding of the PD-1 present on activated lym-
phocytes and PD-L1/PD-1 interaction causes immune
tolerance through apoptosis of the activated lymphocyte
[66-68]. MDX-1106 is a genetically engineered fully
human immunoglobulin G4 monoclonal antibody speci-
fic for human PD-1 [69]. A phase 1 study of anti-PD-1
antibody, MDX-1106, demonstrated single agent
responses in a variety of previously treated, refractory
solid tumors including melanoma with few treatment-
related immune toxicities [69]. The clinical experience
with anti-PD1 treatment is limited but encouraging and
a dose escalation study of the combination of MDX-
1106 and ipilimumab is currently recruiting [43]. In
addition to antibodies that target PD-1, phase 1 trials of
anti-PD-L1 are also underway.
Adoptive T cell therapy
The presence of tumor infiltrating lymphocytes (TIL) in
resected melanoma samples is one of the reasons mela-
noma is often characterized as an immunogenic
Table 3 Summary of C-KIT Trials
Trial Patients RR%
(CR/
PR)
PFS
(month)
OS Number
(patients)
Summary
Single
Arm
Phase 2
Kim KB
et al. [52]
Imatinib mesylate 400 mg bid
in advanced unresectable
melanoma
5% 1.4 7.5
months
21 Imatinib mesylate demonstrated a response in 1 patient who
also had high c-kit expression and alternate splicing variant in c-
kit mRNA transcript.
Single
Arm
Phase 2
Carvajal
et al. [54]
Imatinib mesylate 400 mg bid
in advanced unresectable
melanoma
16% 3 46.3
weeks
28 Imatinib mesylate demonstrated a significant clinical response in
subset of patients with cKit mutation and advanced melanoma
a
Single
Arm
Phase 2
Guo et
al. [53]
Imatinib mesylate 400 mg daily
in metastatic melanoma
23.3% 3.5 14
months
43 Imatinib mesylate demonstrated a significant clinical response in
a subset of patients with cKit mutation and metastatic
melanoma
a
athe clustering of responses in both trials were seen in patients harboring c-kit mutations at exon 11 or exon 13; c-kit overexpression on IHC without a mutation
did not correlate with a response. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.
Table 4 Summary of VEGF Trials
Trial Patients RR%
(CR/
PR)
PFS
(months)
OS
(months)
Number
(patients)
Summary
Single Arm
Phase 2
Perez et al.
[61]
Carboplatin plus paclitaxel and bevacizumab
in unresectable metastatic melanoma
17 6 12 53 Carboplatin plus paclitaxel and
bevacizumab was well tolerated and
clinically beneficial
Randomized
Phase 2
Kim et al.
[62]
Carboplatin plus paclitaxel and bevacizumab
versus
Carboplatin plus paclitaxel in untreated
metastatic melanoma
25.5
versus
16.4
5.6
versus
4.2
12.3
versus
8.6
214 Carboplatin plus paclitaxel and
bevacizumab demonstrated statistically
significant improvement in OS
Single Arm
Phase 2
Kottschade
et al. [63]
Carboplatin plus nab-paclitaxel in
chemotherapy naïve(CN) and previously
treated (PT) metastatic melanoma
25.6
(CN)
8.8
(PT)
4.5 (CN)
4.1 (PT)
11.1 (CN)
10.1 (PT)
41 (CN)
35 (PT)
Carboplatin plus nab-paclitaxel has clinical
activity in chemotherapy naïve patients
Single Arm
Phase 2
Fruehauf et
al. [64]
Axitinib
a in metastatic melanoma after
maximum on one prior therapy
18.8% 3.9 6.6 32 Axitinib demonstrated clinical activity in
metastatic melanoma.
aAxitinib is an oral second-generation inhibitor of VEGF receptors 1, 2, and 3. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial
response RR, response rate.
Finn et al. BMC Medicine 2012, 10:23
http://www.biomedcentral.com/1741-7015/10/23
Page 6 of 10malignancy. Attempts to isolate, expand and infuse TIL
for the treatment of cancer is termed adoptive cell ther-
apy (ACT) and has shown promise for the treatment of
patients with metastatic melanoma [70-73]. Early studies
using TIL and IL-2 produced a response rate of 34%.
Later studies using nonmyeloblative lymphodepletion
with cytotoxic chemotherapy, with or without total body
irradiation, induced response rates as high as 72%
[70-75]. One of the limitations of ACT is that TIL
expansion is not possible for all patients although it was
recently reported that TIL is successfully generated in >
60% of all patients with melanoma and this figure is
even higher in patients who did not receive prior che-
motherapy [76]. In order to circumvent the process of
tumor resection and isolation of TIL, investigators have
developed methods to genetically modify autologous
peripheral T cells to express a T cell receptor that tar-
gets melanoma antigens. This approach has induced a
response rate in a subset of patients with melanoma and
a similar approach has also yielded results in patients
with refractory chronic lymphocytic leukemia [77]. In
summary, ACT for the treatment of melanoma is a pro-
mising, albeit resource consuming method for the treat-
ment of metastatic melanoma.
Interleukin-2
With the approval of ipilimumab, the role of HD IL-2
remains in question. While the clinical benefit of HD
IL-2 is roughly similar to ipilimumab, the toxicity is
worse and tolerability is less. Multiple strategies have
attempted to identify biomarkers to predict clinical
benefit of HD IL-2. Recently, a retrospective study
f o u n dt h a tp a t i e n t sw i t ha nN R A Sm u t a t i o nh a v ea
higher likelihood to respond to HD IL-2 [78]. In addi-
tion, a prospective study of patients with metastatic
melanoma and renal cell carcinoma found that ele-
vated pre-treatment serum VEGF and fibronectin are
inversely correlated with the response rate to HD-IL-2
[79]. Both of these findings require further study at
additional centers before changing clinical practice.
Multiple efforts to increase the response rate of HD
IL-2 while maintaining the duration of response have
been attempted. The addition of a peptide vaccine (gp-
100) to HD IL-2 demonstrated an improved objective
response rate (16% versus 6%, P = 0.03) and overall
survival (17.8 versus 11.1 months, P =0 . 0 6 )[ 8 0 ] .
There are plans to improve upon this finding by using
more potent vaccines.
Finally, it is becoming more evident that patients
who progress on HD IL-2 do derive clinical benefit
from ipilimumab. In the phase 3 study of previously
treated patients, patients who progressed on prior
HD-IL-2 received a similar benefit to ipilimumab as
those who did not [24]. Similarly, a retrospective
study analyzing patients who progressed on HD IL-2
and then received ipilimumab had a response rate
(19%) and OS (12 months) to ipilimumab that was
similar to previously reported historical controls [81].
Given the lack of approved agents and the limited but
quantifiable benefit, we believe there still remains a
role for HD IL-2 in patients who are fit enough to
receive it.
Combined immune and targeted therapy
As we learn more about the molecular pathways and
immune modulation of melanoma, novel combinations
of immune and targeted therapies have the potential of
overcoming the low response rates of immune therapy
and the short durations of response in targeted thera-
pies. Pre-clinical work has suggested that BRAF inhibi-
tion leads to increased tumor recognition by T-cells
providing a rational for the combination of BRAF inhibi-
tors with agents that stimulate the immune system such
as ipilimumab [82]. In addition, BRAF inhibitors and
other targeted therapies will likely be combined with ipi-
limumab, IL-2, anti-PD-1, and other immunotherapies
that are currently being tested.
Role of surgery in metastatic disease
Patients with oligometastatic disease present a clinical
dilemma of whether to treat systemically or locally.
Highly selected patients with isolated lung or liver
metastasis, good performance status, and less aggressive
tumor biology have benefited from metastasectomy with
improved five-year survival rates and median OS rates
of 20 to 25 months [83-87]. Again, patient selection is
the key for success in this setting. A recent phase 2
study enrolled 77 patients for complete resection of
metastatic disease and demonstrated a relapsed free sur-
vival of five months and 36% of patients alive at three
years [88]. While this trial demonstrates that long-term
survival can be achieved through surgery, the trial did
not further identify patients more likely to benefit from
surgery. Currently, a prospective trial of patients with
oligometastatic disease is randomizing patients to either
surgery versus systemic therapy. This will hopefully shed
more light on which patients are most likely to benefit
from metastasectomy.
Conclusions
In 2011, the FDA approval of vermurafenib and ipilimu-
mab instilled optimism in clinicians treating patients
with metastatic melanoma. While these therapies have
limitations, many promising strategies exist to overcome
these limitations. Understanding and overcoming resis-
tance pathways, combining current and future agents,
identifying biomarkers to improve patient selection, and
Finn et al. BMC Medicine 2012, 10:23
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Page 7 of 10discovering future therapeutic targets will hopefully lead
to further treatment advances.
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